Author(s): Banerjee A, KoziolWhite C, Panettieri R Jr
Abstract Share this page
Abstract COPD represents a major respiratory disorder, causing significant morbidity and mortality throughout the world. While therapies exist for COPD, they are not always effective, and many patients experience exacerbations and morbidity despite current therapies. Study of the molecular mechanisms involved in the underlying physiological manifestations of COPD has yielded multiple new targets for therapeutic intervention. In this review, we discuss signaling pathways involved in COPD pathogenesis and review clinical studies of p38 MAPK inhibitors, TNFα inhibitors, and IKK2 inhibitors as potential COPD therapies. Copyright © 2012 Elsevier Ltd. All rights reserved.
This article was published in Curr Opin Pharmacol
and referenced in Journal of Clinical & Cellular Immunology